Related references
Note: Only part of the references are listed.Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies
Brian A. Baldo
ANTIBODIES (2022)
Unlocking the potential of antibody-drug conjugates for cancer therapy
Joshua Z. Drago et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency
Dian Su et al.
FRONTIERS IN PHARMACOLOGY (2021)
Introduction to Antibody-Drug Conjugates
Mark C. Pettinato
ANTIBODIES (2021)
Protease-activated prodrugs: strategies, challenges, and future directions
Marcin Poreba
FEBS JOURNAL (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Bob T. Li et al.
CANCER DISCOVERY (2020)
Targeting apoptosis in cancer therapy
Benedito A. Carneiro et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
TUMOR CELL-INTRINSIC STING PATHWAY IS ACTIVATED IN THE PRESENCE OF CUES FROM IMMUNE CELLS AND CONTRIBUTES TO THE ANTI-TUMOR ACTIVITY OF TUMOR CELL-TARGETED STING AGONIST ANTIBODY-DRUG CONJUGATES
Naniye Malli Cetinbas et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Nature-derived anticancer steroids outside cardica glycosides
Jiaqi Xiao et al.
FITOTERAPIA (2020)
Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates
Guolan Lu et al.
NATURE COMMUNICATIONS (2020)
Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment
Chunlin Zhuang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Michael J. Birrer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy
Jeffrey C. Kang et al.
NATURE BIOTECHNOLOGY (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A systemically administered, conditionally active TLR8 agonist for the treatment of HER2-expressing tumors
Kara Moyes et al.
CANCER RESEARCH (2019)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models
Lin Yu et al.
ONCOTARGET (2018)
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
Ricarda M. Hoffmann et al.
ONCOIMMUNOLOGY (2018)
Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification
Dian Su et al.
BIOCONJUGATE CHEMISTRY (2018)
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Fate of Antibody-Drug Conjugates in Cancer Cells
Cecile Chalouni et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice
Yasuaki Anami et al.
NATURE COMMUNICATIONS (2018)
Targeted radionuclide therapy in combined-modality regimens
Martin R. Gill et al.
LANCET ONCOLOGY (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
C. A. van der Weyden et al.
BLOOD CANCER JOURNAL (2017)
Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates
Muhammad Kalim et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H. Staudacher et al.
BRITISH JOURNAL OF CANCER (2017)
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
Mohammad A. Sabbaghi et al.
CLINICAL CANCER RESEARCH (2017)
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates
Xiuxia Sun et al.
BIOCONJUGATE CHEMISTRY (2017)
Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis
Erika A. Crane et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Antibody drug conjugates: lessons from 20 years of clinical experience
A. W. Tolcher
ANNALS OF ONCOLOGY (2016)
Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
Hans-Peter Gerber et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Antibody-drug conjugates-an emerging class of cancer treatment
Nikolaos Diamantis et al.
BRITISH JOURNAL OF CANCER (2016)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
Fu Li et al.
CANCER RESEARCH (2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Pia M. Challita-Eid et al.
CANCER RESEARCH (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?
Janine Schuurman et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Linkers Having a Crucial Role in Antibody-Drug Conjugates
Jun Lu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
Aman P. Singh et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates
Jeffrey C. Kern et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography
Anand Giddabasappa et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Expanding the Reach of Antibody-Drug Conjugates
Ravi V. J. Chari
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
Andrew B. Waight et al.
PLOS ONE (2016)
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
Eunhee G. Kim et al.
BIOMOLECULES & THERAPEUTICS (2015)
Antibody-drug conjugates as novel anti-cancer chemotherapeutics
Christina Peters et al.
BIOSCIENCE REPORTS (2015)
Emerging formats for next-generation antibody drug conjugates
Mahendra P. Deonarain et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents
Giulio Casi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
M. Pfeifer et al.
LEUKEMIA (2015)
AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Kevin J. Hamblett et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Frank Loganzo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Mechanisms of action of therapeutic antibodies for cancer
J. M. Redman et al.
MOLECULAR IMMUNOLOGY (2015)
Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates
Andreas Maderna et al.
MOLECULAR PHARMACEUTICS (2015)
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985
Ronald C. Elgersma et al.
MOLECULAR PHARMACEUTICS (2015)
Current ADC Linker Chemistry
Nareshkumar Jain et al.
PHARMACEUTICAL RESEARCH (2015)
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Laleh Amiri-Kordestani et al.
CLINICAL CANCER RESEARCH (2014)
Antibody-drug conjugates: current status and future directions
Heidi L. Perez et al.
DRUG DISCOVERY TODAY (2014)
Site-specific antibody drug conjugates for cancer therapy
Siler Panowski et al.
MABS (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
Antibody-Drug Conjugates in Cancer Therapy
Eric L. Sievers et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
May S. Kung Sutherland et al.
BLOOD (2013)
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
Man Yu et al.
CANCER AND METASTASIS REVIEWS (2013)
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Oktay Tacar et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Milatuzumab-SN-38 Conjugates for the Treatment of CD74 Cancers
Serengulam V. Govindan et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
Michael Ritchie et al.
MABS (2013)
Maturing antibody-drug conjugate pipeline hits 30
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2013)
AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
David B. Rosen et al.
PLOS ONE (2013)
Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum
Keyang Xu et al.
BIOANALYSIS (2013)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A mechanistic compartmental model for total antibody uptake in tumors
Greg M. Thurber et al.
JOURNAL OF THEORETICAL BIOLOGY (2012)
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
Hyesil Seol et al.
MODERN PATHOLOGY (2012)
Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin
Taichi Matsumoto et al.
LEUKEMIA & LYMPHOMA (2012)
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D. Senter et al.
NATURE BIOTECHNOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2011)
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Mohammad Tabrizi et al.
AAPS JOURNAL (2010)
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Yelena V. Kovtun et al.
CANCER RESEARCH (2010)
Antibody-drug conjugates: targeted drug delivery for cancer
Stephen C. Alley et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR
Marie Brevet et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules
Manu Lopus et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability
Emin Oroudjev et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML
Petra Haag et al.
EXPERIMENTAL HEMATOLOGY (2009)
Targeted cancer therapy: Conferring specificity to cytotoxic drugs
Ravi V. J. Chari
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Antibody-drug conjugates for cancer therapy
Paul J. Carter et al.
CANCER JOURNAL (2008)
Paul Ehrlich's magic bullet concept: 100 years of progress
Klaus Strebhardt et al.
NATURE REVIEWS CANCER (2008)
Cell killing by antibody-drug conjugates
Yelena V. Kovtun et al.
CANCER LETTERS (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma
Michael F. Leahy et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Monoclonal antibody therapy
D O'Mahony et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2006)
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
HK Erickson et al.
CANCER RESEARCH (2006)
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
MSK Sutherland et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity
I Jedema et al.
LEUKEMIA (2004)
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both
EA Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients
VHJ van der Velden et al.
LEUKEMIA (2004)
Regulated portals of entry into the cell
SD Conner et al.
NATURE (2003)
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-Doxorubicin in patients with Lewis Y-expressing epithelial tumors
MN Saleh et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
